Press Releases

April 21, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO , April 21, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, announced the

PDF Version
April 16, 2020 at 9:10 AM EDT

Summary Toggle Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock

SAN DIEGO , April 16, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced the

PDF Version
April 15, 2020 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO , April 15, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it intends to

PDF Version
April 13, 2020 at 8:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency

Clinical Plan Includes Healthy Volunteers in New Zealand and OTC-Deficient Patients Across Several Sites in United States Investor Conference Call at 4:00 pm ET Today SAN DIEGO , April 13, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading clinical-stage

PDF Version
April 9, 2020 at 7:00 AM EDT

Summary Toggle Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine

GMP-Manufactured Batch to be Delivered in June 2020 Human Dosing Expected to Begin in Summer 2020 SAN DIEGO , April 09, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and

PDF Version
March 27, 2020 at 7:00 AM EDT

Summary Toggle Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System

Data will help Arcturus learn more quickly about LUNAR-COV19 efficacy and safety profile SAN DIEGO , March 27, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines and vaccines company, today provided details about the Company’s strategy to

PDF Version
March 11, 2020 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results

IND Filed for Flagship Program ARCT-810 Coronavirus Vaccine Program Initiated Investor Conference Call at 4:30 pm ET Today SAN DIEGO, Calif. , March 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery,

PDF Version
March 4, 2020 at 7:30 AM EST

Summary Toggle Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology

Collaboration seeks to conduct pre-clinical testing followed by first-in-human clinical trials SAN DIEGO and SINGAPORE , March 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company, and Duke-NUS Medical School (Duke-NUS), a

PDF Version
February 24, 2020 at 7:30 AM EST

Summary Toggle Arcturus Therapeutics to Report Fourth Quarter and Year-End 2019 Financial Results and Provide Corporate Update on March 11

SAN DIEGO , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it will provide a corporate overview and

PDF Version
February 19, 2020 at 7:30 AM EST

Summary Toggle Arcturus Therapeutics to Present at Two Investor Conferences in March

SAN DIEGO , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Joseph Payne , Chief Executive Officer,

PDF Version